Nxera Pharma Co., Ltd.
4565.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | ¥29 | ¥13 | ¥16 | ¥18 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Cost of Goods Sold | ¥8 | ¥3 | ¥1 | ¥1 |
| Gross Profit | ¥21 | ¥10 | ¥15 | ¥17 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| R&D Expenses | ¥12 | ¥10 | ¥7 | ¥6 |
| G&A Expenses | ¥16 | ¥10 | ¥4 | ¥4 |
| SG&A Expenses | ¥16 | ¥10 | ¥4 | ¥4 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | -¥1 | -¥1 | -¥1 | ¥3 |
| Operating Expenses | ¥27 | ¥19 | ¥11 | ¥13 |
| Operating Income | -¥5 | -¥10 | ¥3 | ¥7 |
| % Margin | -18.8% | -74.6% | 18.1% | 39% |
| Other Income/Exp. Net | ¥1 | -¥1 | -¥2 | -¥6 |
| Pre-Tax Income | -¥5 | -¥11 | ¥1 | ¥0 |
| Tax Expense | ¥0 | -¥3 | ¥1 | -¥1 |
| Net Income | -¥5 | -¥7 | ¥0 | ¥1 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS | -53.92 | -87.17 | 4.67 | 12.53 |
| % Growth | 38.1% | -1,966.6% | -62.7% | – |
| EPS Diluted | -53.92 | -87.17 | 4.63 | 12.4 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥2 | ¥1 | ¥1 | ¥0 |
| Interest Expense | ¥1 | ¥2 | ¥1 | ¥4 |
| Depreciation & Amortization | ¥4 | ¥2 | ¥1 | ¥1 |
| EBITDA | ¥0 | -¥6 | ¥4 | ¥2 |
| % Margin | 0.4% | -44.7% | 22.9% | 12.4% |